Skip to navigation Skip to content

Refractory follicular B-cell non-Hodgkin's lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051115

Expand/Collapse all sectionsExpand all



This document outlines details of the previous Pharmaceutical Benefits Scheme (PBS) subsidised idelalisib for patients with Refractory follicular B-cell non-Hodgkin's lymphoma (FBHL).

This program has been moved to the general schedule from 1 January 2022 and this page is for informational purposes only.

Refractory follicular B-cell non-Hodgkin’s lymphoma and listing dates

Refractory follicular B-cell non-Hodgkin’s lymphoma (FBHL) is a type of blood cancer.

Listing date: idelalisib - 1 September 2017.

For further details, see Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA).

Enquiries

Transfer enquiries about prescription arrangements to the PBS authority approvals line.

Related links

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)